Publications by authors named "Kyle A Edgar"

Claim this Profile
D
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα.
Emily J Hanan, Marie-Gabrielle Braun, Robert A Heald, Calum MacLeod, Connie Chan, Kyle A Edgar

J Med Chem· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy.
Kyung W Song, Kyle A Edgar, Emily J Hanan, Marc Hafner, Jason Oeh

Cancer Discov· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of PI3K Inhibition on Afucosylated Antibody-Driven FcγRIIIa Events and Phospho-S6 Activity in NK Cells.
Valentina Romeo, Sarah Gierke, Kyle A Edgar, Scot D Liu

J Immunol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase.
Klaus P Hoeflich, Jane Guan, Kyle A Edgar, Carol O'Brien, Heidi Savage

Genes Cancer· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition.
Kyle A Edgar, Lisa Crocker, Eric Cheng, Marie-Claire Wagle, Matthew Wongchenko

Genes Cancer· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity.
Chudi O Ndubaku, Timothy P Heffron, Steven T Staben, Matthew Baumgardner, Nicole Blaquiere, Kyle A Edgar

J Med Chem· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncogenic ERBB3 mutations in human cancers.
Bijay S Jaiswal, Noelyn M Kljavin, Eric W Stawiski, Emily Chan, Chaitali Parikh, Kyle A Edgar

Cancer Cell· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes.
Jeffrey J Wallin, Jane Guan, Kyle A Edgar, Wei Zhou, Ross Francis

PLoS One· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier.
Laurent Salphati, Timothy P Heffron, Bruno Alicke, Merry Nishimura, Kai Barck, Kyle A Edgar

Clin Cancer Res· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Jeffrey J Wallin, Kyle A Edgar, Jane Guan, Megan Berry, Wei Wei Prior

Mol Cancer Ther· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
Laurent Salphati, Harvey Wong, Marcia Belvin, Delia Bradford, Kyle A Edgar

Drug Metab Dispos· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer.
Jeffrey J Wallin, Jane Guan, Wei Wei Prior, Kyle A Edgar, Robert Kassees

Sci Transl Med· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A hierarchy of self-renewing tumor-initiating cell types in glioblastoma.
Ruihuan Chen, Merry C Nishimura, Stephanie M Bumbaca, Samir Kharbanda, William F Forrest, Kyle A Edgar

Cancer Cell· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
Kyle A Edgar, Jeffrey J Wallin, Megan Berry, Leslie B Lee, Wei Wei Prior

Cancer Res· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthetic lethality of retinoblastoma mutant cells in the Drosophila eye by mutation of a novel peptidyl prolyl isomerase gene.
Kyle A Edgar, Marcia Belvin, Annette L Parks, Kellie Whittaker, Matt B Mahoney

Genetics· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic generation of high-resolution deletion coverage of the Drosophila melanogaster genome.
Annette L Parks, Kevin R Cook, Marcia Belvin, Nicholas A Dompe, Robert Fawcett, Kyle A Edgar

Nat Genet· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis